MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1210/jc.2017-01555

Медицинская библиотека · The Journal of clinical endocrinology and metabolism · 2018

PTH(1-34) for Surgical Hypoparathyroidism: A 2-Year Prospective, Open-Label Investigation of Efficacy and Quality of Life.

Palermo Andrea, Santonati Assunta, Tabacco Gaia, Bosco Daniela, Spada Antonio, Pedone Claudio, Raggiunti Bruno, Doris Tina, Maggi Daria, Grimaldi Franco, Manfrini Silvia, Vescini Fabio

СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

CONTEXT: Daily parathyroid hormone (PTH) (1-34) administrations can reduce the required total daily dose of calcium and calcitriol and restore normocalcemia in refractory hypoparathyroidism. However, most PTH(1-34) trials have been conducted on small cohorts including subjects with hypoparathyroidism of various etiologies, and quality of life (QOL) was not investigated.

OBJECTIVE

To investigate the effects of 24-month PTH(1-34) treatment in a homogeneous cohort of adult subjects with postoperative hypoparathyroidism and to evaluate QOL changes.

DESIGN

Prospective open-label study.

SETTING

Italian multicenter study.

PARTICIPANTS

42 subjects.

INTERVENTION: Twice-daily PTH(1-34) 20 μg subcutaneous injection.

MAIN OUTCOME MEASURES: Calcium and vitamin D supplementation requirements, serum calcium, phosphate, and urinary calcium excretion (3, 6, 12, 18, 24 months). At baseline and at 6 and 24 months, QOL was evaluated by the RAND 36-Item Short Form (SF-36) Health Survey, covering eight domains of physical and mental health.

RESULTS

Mean serum calcium concentration significantly increased from baseline to 3 months (7.6 ± 0.6 vs 8.9 ± 1.1 mg/dL, P < 0.001) and remained stable until the end of the study, despite reductions in calcium and vitamin D supplementation. Phosphate levels gradually decreased from baseline to 6 months (4.3 ± 1.1 vs 3.9 ± 0.6 mg/dL, P < 0.019), remaining stable until 24 months. Serum alkaline phosphatase and calcium excretion gradually increased from baseline to 24 months. Data from SF-36 showed a significant improvement in the mean scores of all eight domains (P < 0.001).

CONCLUSION

This study demonstrates the efficacy and safety of PTH(1-34) to treat adult patients with postsurgical hypoparathyroidism. PTH(1-34) may improve their mental and physical health.

Для цитирования: Palermo Andrea, Santonati Assunta, Tabacco Gaia, Bosco Daniela, Spada Antonio, Pedone Claudio, Raggiunti Bruno, Doris Tina, Maggi Daria, Grimaldi Franco, Manfrini Silvia, Vescini Fabio. PTH(1-34) for Surgical Hypoparathyroidism: A 2-Year Prospective, Open-Label Investigation of Efficacy and Quality of Life.. The Journal of clinical endocrinology and metabolism. 2018. DOI: 10.1210/jc.2017-01555.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.